Relief Therapeutics Holding (XSWX:RLF) GF Value Rank: 2 (As of Jul. 05, 2026) — Near Median


XSWX:RLF Relief Therapeutics Holding SA XSWX:RLF
20 GF Score
Price CHF3.00
GF Value CHF6.28
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding GF Value Rank?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 GF Value Rank is 2 as of Jul. 05, 2026, which is at its 10-year median of 2.00. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

Relief Therapeutics Holding has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Relief Therapeutics Holding GF Value Rank Related Terms


XSWX:RLF vs KTTA, OSRH, LIMN: GF Value Rank Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's GF Value Rank falls into.


XSWX:RLF
20GF Score
Relief Therapeutics Holding SA XSWX:RLF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Relief Therapeutics Holding (XSWX:RLF) has a GF Value Rank of 2 as of Jul. 05, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Relief Therapeutics Holding and its competitors. This is near median its historical median of 2.00. Over the past decade, Relief Therapeutics Holding's GF Value Rank has ranged from 2.00 to 4.00.
Is Relief Therapeutics Holding's GF Value Rank too high?
Relief Therapeutics Holding's current GF Value Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.00. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's GF Value Rank compare to KTTA and OSRH?
Relief Therapeutics Holding's GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Relief Therapeutics Holding's own GF Value Rank has ranged from 2.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current GF Value Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current GF Value Rank of 2. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current GF Value Rank is 2, which is near median its 10-year median of 2.00. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current GF Value Rank is 2 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

  • GF Value Rank: 2 (near median its 10-year median of 2.00)
  • GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score

Get the complete analysis for XSWX:RLF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00
Price
CHF6.28
GF Value